TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tonix Pharmaceuticals Holding Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.73−0.31 (-5.13%)
Close on Oct 19, 2026
- Market cap
- $95.32M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
49.3%
Operating margin
-959.1%
Net margin
-946.2%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +29.8% | – | – | – | |
| Gross profit | +177.7% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -118.4% | -104.0% | -64.5% | |
| Return on assets | -104.2% | -89.5% | -56.4% | |
| Current ratio | 12.83 | 8.96 | 7.42 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | – | -1412.4× | |
| Capex to revenue | – | – | 25.7% | |
| Diluted shares | 0M | 0M | 9M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Tonix Pharmaceuticals generated $436.38M from operations and spent $122.56M on capital expenditure, dividends and share buybacks. 77% of that went back into the business.
Generated
$436.38M
Used
$122.56M
Capital expenditure$94.84M77%Dividends$00%Share buybacks$27.73M23%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-946.2%
×Asset turnover0.06×
×Equity multiplier1.14×
=Return on equity, FY2025-64.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -946.2% | 0.06× | 1.14× | -64.5% |
| FY2024 | -1288.3% | 0.06× | 1.29× | -106.1% |
| FY2023 | -1501.8% | 0.04× | 1.22× | -74.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$124.02M
- Cash generatingOperating cash flow above zero-$99.84M
- Return on assets improvedROA up on the prior year-84.2% → -76.1%
- Earnings backed by cashOperating cash flow above net income-$99.84M vs -$124.02M
- Less leverageLong-term debt to assets fell2.9% → –
- Better liquidityCurrent ratio rose6.50 → 7.42
- No dilutionShare count did not rise1M → 9M
- Gross margin improvedGross margin up on the prior year23.07% → 49.34%
- More efficientAsset turnover rose0.07 → 0.08